JUSMEDICO ADVOKATANPARTSSELSKAB - CVR: 30728106

2022, DKK

22.06.2023

Bruttoresultat

1.040'

Primær drift

328'

Årets resultat

249'

Aktiver

1.908'

Kortfristede aktiver

1.757'

Egenkapital

1.541'

Afkastningsgrad

17 %

Soliditetsgrad

81 %

Likviditetsgrad

+500%

Resultat

22.06.2023

Årsrapport	2022 22.06.2023	2021 10.06.2022	2020 25.06.2021	2019 20.04.2020	2018 04.06.2019	2017 31.05.2018	2016 12.06.2017	2015 29.04.2016
Nettoomsætning	1.618.546	2.071.121	3.145.265	3.028.683	3.017.345	2.041.313	2.246.763	1.765.763
Bruttoresultat	1.040.083	1.387.977	2.246.547	2.008.167	2.160.556	1.395.824	1.498.312	1.212.951
Resultat af primær drift	327.867	577.888	702.104	990.103	1.043.022	2.959	555.518	304.336
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0	0
Finansielle indtægter	314	3.189	140	167	443.102	588.862	570.317	148.053
Finansieringsomkostninger	-7.236	-9.827	-19.391	-15.839	-22.393	-29.448	-7.128	-599
Andre finansielle omkostninger	0	0	0	0	0	0	0	0
Resultat før skat	320.945	571.250	682.853	974.431	1.463.731	562.373	1.118.707	443.276
Resultat	248.562	443.137	530.382	757.499	1.139.658	435.037	813.743	283.969
Forslag til udbytte	-800.000	-400.000	-530.382	-1.249.298	-1.139.658	-105.800	-103.400	-101.200

Aktiver

22.06.2023

Årsrapport	2022 22.06.2023	2021 10.06.2022	2020 25.06.2021	2019 20.04.2020	2018 04.06.2019	2017 31.05.2018	2016 12.06.2017	2015 29.04.2016
Kortfristede varebeholdninger	0	0	0	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	1.454.058	2.180.760	1.586.502	1.195.222	1.289.227	2.556.554	2.199.015	1.780.072
Likvider	302.635	198.664	1.007.718	1.747.951	2.973.722	512.209	233.030	310.725
Kortfristede aktiver	1.756.693	2.379.424	2.594.220	2.943.173	4.262.949	5.680.588	5.352.226	3.980.007
Immaterielle aktiver og goodwill	0	0	0	0	0	0	0	235.998
Finansielle anlægsaktiver	28.500	105.104	105.967	103.466	101.863	14.708	14.708	14.708
Materielle aktiver	122.889	44.521	111.302	416.448	496.347	0	0	0
Langfristede aktiver	151.389	149.625	217.269	519.914	598.210	14.708	14.708	250.706
Aktiver	1.908.082	2.529.049	2.811.489	3.463.087	4.861.159	5.695.296	5.366.934	4.230.713

Aktiver

22.06.2023

Passiver

22.06.2023

Årsrapport	2022 22.06.2023	2021 10.06.2022	2020 25.06.2021	2019 20.04.2020	2018 04.06.2019	2017 31.05.2018	2016 12.06.2017	2015 29.04.2016
Forslag til udbytte	800.000	400.000	530.382	1.249.298	1.139.658	105.800	103.400	101.200
Egenkapital	1.540.939	1.692.376	1.779.621	2.498.538	2.880.697	5.007.867	4.676.230	3.963.687
Hensatte forpligtelser	21.547	27.889	23.364	45.487	42.018	0	0	0
Langfristet gæld til banker	0	0	0	0	0	0	0	0
Anden langfristet gæld	0	0	0	0	0	0	0	0
Leverandører af varer og tjenesteydelser	48.200	52.076	72.352	67.621	66.457	240.386	91.271	4.606
Kortfristede forpligtelser	345.596	808.784	1.008.504	919.062	1.938.444	687.429	690.704	267.026
Gældsforpligtelser	345.596	808.784	1.008.504	919.062	1.938.444	687.429	690.704	267.026
Forpligtelser	345.596	808.784	1.008.504	919.062	1.938.444	687.429	690.704	267.026
Passiver	1.908.082	2.529.049	2.811.489	3.463.087	4.861.159	5.695.296	5.366.934	4.230.713

Passiver

22.06.2023

Nøgletal

22.06.2023

Årsrapport	2022 22.06.2023	2021 10.06.2022	2020 25.06.2021	2019 20.04.2020	2018 04.06.2019	2017 31.05.2018	2016 12.06.2017	2015 29.04.2016
Afkastningsgrad	17,2 %	22,9 %	25,0 %	28,6 %	21,5 %	0,1 %	10,4 %	7,2 %
Dækningsgrad	64,3 %	67,0 %	71,4 %	66,3 %	71,6 %	68,4 %	66,7 %	68,7 %
Resultatgrad	15,4 %	21,4 %	16,9 %	25,0 %	37,8 %	21,3 %	36,2 %	16,1 %
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	16,1 %	26,2 %	29,8 %	30,3 %	39,6 %	8,7 %	17,4 %	7,2 %
Payout-ratio	321,9 %	90,3 %	100,0 %	164,9 %	100,0 %	24,3 %	12,7 %	35,6 %
Gældsdæknings-nøgletal	4.531,1 %	5.880,6 %	3.620,8 %	6.251,0 %	4.657,8 %	10,0 %	7.793,5 %	50.807,3 %
Soliditestgrad	80,8 %	66,9 %	63,3 %	72,1 %	59,3 %	87,9 %	87,1 %	93,7 %
Likviditetsgrad	508,3 %	294,2 %	257,2 %	320,2 %	219,9 %	826,4 %	774,9 %	1.490,5 %

Resultat

22.06.2023

Gæld

22.06.2023

Årsrapport

22.06.2023

Nyeste:01.01.2022- 31.12.2022(offentliggjort: 22.06.2023)

Information om virksomhedens regnskabsklasse:The annual report of Jusmedico Advokatanpartsselskab for 2022 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

Beretning

22.06.2023

Dato for ledelsens godkendelse af årsrapporten:2023-06-21

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Executive Board has discussed and approved the annual report of Jusmedico Advokatanpartsselskab for the financial year 1 January - 31 December 2022.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Jusmedico Law Firm Ltd. Advokatanpartsselskab (“Jusmedico”), is a specialist law firm providing legal ser-vices to the biotech, pharmaceutical, medical device and dentistry industries, life science investors and to suppliers and service providers thereto. The working areas of Jusmedico include research & development, pre-clinical test and clinical trial, data protection, production & supply, labelling & packaging, licensing, co-promotion & co-marketing agreements, agent and distribution agreements, as well as advertising & promotion advice. In addition Jusmedico renders legal advice to life science clients on third party liability insurance pro-grams providing cover for clinical testing of investigational medicinal products and D&O programs. Internationally Jusmedico is a founding member of the BioLawEurope Alliance comprising a network of inde-pendent European law firms, please refer to http://www. jusmedico. com/biolaweurope, and individual attor-neys licensed in one or more EU-, EFTA-, - and/or UK jurisdictions, providing legal services focusing on the same legal disciplines as Jusmedico. Further Jusmedico operates a representative office in New York, USA, see https://jusmedicolaw. com/ Jusmedico, which was established in May 2004, was transformed into a private limited company on 1 January 2007. Notwithstanding the transformation each attorney employed remained and remains personally liable for legal advice rendered under contract prior to and after the transformation. During 2022 Jusmedico has continued its co-operation with the members of its Advisory Board established in 2007. The Advisory Board comprises 9 professionals, including 7 specialists within the fields of research, pa-tenting, clinical development, insurance, regulatory service, quality management, start-up tax planning and accounting. These areas of expertise are especially relevant to Jusmedico's client portfolio, which comprises clients operating on a private commercial basis as well as on a non-profit public basis. The chairman of the Jusmedico Advisory Board is counselor at law Brian M. Hand, Esq. , Jusmedico Law Group, New York, who is also in charge of Jusmedico’s representative office in the USA. Jusmedico has in 2022 assumed the role as secretary and treasurer of the BioLawEurope Alliance, which in 2022 held its 8th Annual Meeting in Berlin, Germany. The meeting was hosted by the German member of the Alliance, Dierks+Company founded in 2018 by Prof. Dr. med. Dr. iur. Christian Dierks and Juliana Dierks. Christian is one of the leading lawyers for medical law in Germany and Europe, a trained physician, an expert in regulatory issues, reimbursement, digital health and a professor for health services research at Charite Ber-lin. In addition to activities via the BioLawEurope Alliance and referrals from the representative office in New York, Jusmedico is co-operating nationally with several Danish law firms, which on an ad hoc basis may be in-volved in assignments falling outside Jusmedico’s core competence areas. Jusmedico is primarily co-operating with Bugge Valentin, a full-service IP, marketing practices and tech boutique law firm in Denmark with highly acclaimed litigation skills and track records. Bugge Valentin has also joined the BioLawEurope Al-liance. The BioLawEurope Alliance and the Advisory Board initiatives enable co-operation across the boundaries of individual professions and enable Jusmedico involving all relevant professionals in larger and/or long term client projects. Jusmedico has continued to render services to new life science sector start-ups, including to assist them as their projects develop. In close co-operation with several business angles, Jusmedico has experienced a ten-dency to increase investments in the medical device sector balanced by a corresponding reduction in pharma and biotech. On this basis Jusmedico’s allocation of staff to an EU-supported business angle activity focusing on life science, incl. med tech, and financial service related investments, continues and has generated sepa-rately accounted for turnover. In spite hereof and in spite of the pandemic, the climate crisis and Russia’s con-tinued aggression and war campaigns in Ukraine the 2022 turnover has been satisfactory. In 2023 the activity split will be continued. Jusmedico’s marketing activities primarily comprise participation in the BioLawEurope Alliance, homepage maintenance and lecturing domestically and internationally. In 2021, 2022 and 2023 Jusmedico has been granted the Biotech Law Firm of the Year in Denmark award by INTL Global. The publications and the awards continue to produce international clients, including from Asia. Considering a staff reduction having taken place in 2021, management is satisfied with the Company's reve-nues amounting to MDKK 1,6 in 2022, against MDKK 2,1 in 2021. Management proposes to the general meeting that dividends are paid to the shareholders for 2022 in the amount of TDKK 800.